Biotherapeutic proteins, which include antibodies, are becoming the fastest growing category of drugs due to their efficacy for patient health. The complex nature of these large molecules brings major new challenges to the pharmaceutical scientist. The industry is undergoing a scientific revolution as it adapts to meet the challenges of characterizing biotherapeutics.
In this webinar, we discuss the difficulties of characterize monoclonal antibodies and other similar biotherapeutics and also the current technologies used to maximize glycan separation capabilities and structural elucidation.